JAK1 and acute graft versus host disease: Ruxolitinib is a potent, highly bioavailable JAK1/2 inhibitor that is already US Food and Drug Administration (FDA) approved for the treatment of myelofibrosis, polycythemia vera, steroid-refractory acute graft versus host diseases and atopic dermatitis (84).